Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Ultragenyx Pharmaceu (NQ: RARE ) 42.55 -0.23 (-0.54%) Streaming Delayed Price Updated: 4:00 PM EDT, Jul 19, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Ultragenyx Pharmaceu < Previous 1 2 3 4 5 6 7 8 Next > Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) July 18, 2023 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Ultragenyx Appoints Howard Horn as Chief Financial Officer and Executive Vice President, Corporate Strategy July 12, 2023 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Ultragenyx Announces First Patients Dosed in Phase 3 Program Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI) July 06, 2023 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire The Latest Analyst Ratings for Ultragenyx Pharmaceutical June 06, 2023 Via Benzinga Why Ultragenyx Pharma Stock Is Trading Higher Premarket Today June 06, 2023 Via Benzinga Ultragenyx Pharmaceutical's Return On Capital Employed Insights May 15, 2023 Via Benzinga Ultragenyx Pharmaceutical: Q1 Earnings Insights May 04, 2023 Via Benzinga Ultragenyx Opens New Gene Therapy Manufacturing Facility in Bedford, Continuing its Expansion in Massachusetts June 21, 2023 The company is one of the first in the U.S. with complete end-to-end gene therapy capabilities in Massachusetts, from research and development to therapeutic production at scale From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) June 20, 2023 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Ultragenyx to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference June 07, 2023 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire A Preview Of Ultragenyx Pharmaceutical's Earnings May 03, 2023 Via Benzinga Expert Ratings for Ultragenyx Pharmaceutical April 26, 2023 Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For June 6, 2023 June 06, 2023 Via Benzinga Apple To Rally Around 17%? Here Are 10 Other Analyst Forecasts For Tuesday June 06, 2023 B of A Securities boosted the price target for Molson Coors Beverage Company (NYSE: TAP) from $54 to $68. B of A Securities analyst Bryan Spillane upgraded the stock from Underperform to Neutral.... Via Benzinga Ultragenyx and Mereo BioPharma Announce Positive Data from the Ongoing Phase 2/3 Orbit Study of Setrusumab (UX143) in Osteogenesis Imperfecta (OI) June 05, 2023 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Ultragenyx to Present at the 2023 Barclays - Gene Editing & Gene Therapy Summit May 19, 2023 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) May 18, 2023 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential May 18, 2023 These two mid-cap biotech companies are relatively established in their fields — but according to analysts, still have significant upside. Via MarketBeat Exposures Product Safety Ultragenyx Receives FDA Agreement to Expand Ongoing Global Phase 1/2 Trial Evaluating GTX-102 in Patients with Angelman Syndrome in the U.S. May 17, 2023 Amended U.S. protocol increases loading and maintenance doses to similar range as ex-U.S. expansion cohorts From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Ultragenyx Pharm Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating May 15, 2023 Ultragenyx Pharm shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 77 to 81. Via Investor's Business Daily Ultragenyx Announces Upcoming Data Presentations at American Society of Gene & Cell Therapy (ASGCT) 2023 Annual Meeting May 08, 2023 Oral presentations include longer term durability data from DTX301 and DTX401 and showcase the Pinnacle PCL™ (AAV vector producer cell line) platform and technology From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Ultragenyx to Present at Bank of America’s 2023 Health Care Conference May 05, 2023 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Ultragenyx Reports First Quarter 2023 Financial Results and Corporate Update May 04, 2023 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Ultragenyx to Host Conference Call for First Quarter 2023 Financial Results and Corporate Update April 27, 2023 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Benzinga's Top Ratings Upgrades, Downgrades For April 26, 2023 April 26, 2023 Via Benzinga Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) April 19, 2023 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire 7 Biotech Stocks to Buy for Breakthrough Treatments and Cures March 29, 2023 For those that can handle the heat, these biotech stocks to buy undergird some of the most powerful innovations in medicine. Via InvestorPlace Ultragenyx to Present at Guggenheim’s Genomic Medicines and Rare Disease Days March 28, 2023 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) March 21, 2023 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Ultragenyx Appoints Dr. Eric Crombez Chief Medical Officer and Executive Vice President March 14, 2023 Dr. Camille Bedrosian to continue employment as strategic development advisor with the company From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire < Previous 1 2 3 4 5 6 7 8 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.